MicroPort NeuroTech™ Receives NMPA Marketing Approval for the X-track™ Intracranial Distal Access Catheter

Shanghai, China, 15 April 2022 — MicroPort NeuroTech Limited (MicroPort NeuroTech™) has received marketing approval issued by China’s National Medical Products Administration (NMPA) for its independently-developed X-track™ Intracranial Distal Access Catheter (X-track™).

The continuous sophistication of interventional procedures has put forward higher requirement on the catheter performance for establishing delivery access for medical devices. The approved X-track™ is made of special polymer materials and a braided structure with two filaments that can reach the lesion site repeatedly during the procedure. It also features great fatigue resistance that can fully address the clinical demand for catheter improvement. The combination of materials of different hardness and special treatment to the transition section gives X-track™ great support at the proximal end and flexibility at the distal end, with reduced resistance that allows it to reach more distant lesions. In addition, X-track™ is designed with a large lumen, which is compatible with a variety of procedures and can be used in conjunction with a clot retrieval stent for efficient thrombus removal.

The launch of X-track™ as the first intermediate catheter product for the treatment of cerebrovascular acute ischemic stroke of the company, further enriches MicroPort NueroTech™'s product portfolio for ischemic stroke treatment, combined with Neurohawk® Stent Thrombectomy Device, Diveer® Intracranial Balloon Catheter and APOLLO™ Intracranial Stent System. In the future, MicroPort NueroTech™ will continue to promote product innovation and will keep improving its inclusive and accessible total medical solutions for hemorrhagic stroke, intracranial atherosclerotic stenosis, and acute ischemic stroke.